DraftKings’ bulls were thrown an unexpected curveball, but this new competition doesn’t carry the same brand-name cache. After years of development, Recursion Pharmaceuticals’ AI-powered drug discovery technology should finally, firmly start proving its true value.
Source: https://www.fool.com/investing/2026/01/29/forget-2025-these-…
Data center spending could climb to $7 trillion by 2030, according to McKinsey. Advanced Micro Devices expects revenue to grow at a 35% compound annual rate over the next three to five years.
Sin stocks continue to generate reliable cash flows and robust dividends, offering steady returns despite ethical debates.
Donald Trump signed an executive order on Dec. 18 to fast-track the Food and Drug Administration’s review to reclassify cannabis as a Schedule III substance under the Controlled Substances Act. Pot stocks Trulieve Cannabis, Curaleaf, Cresco Labs, Green Thumb Industries, and Canopy Growth plummeted by up to 39% due to the scope of Trump’s intentions.
